What Colour Is Mounjaro? UK Pen Identification Guide

Mounjaro (tirzepatide) is a once-weekly injectable medication licensed in the UK for type 2 diabetes and weight management. The pre-filled pens use a colour-coded system to help identify different dosage strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Whilst pen colours provide a visual reference, patients must always verify the strength in milligrams printed on the carton and pen label before each injection. Understanding this identification system supports safe medication administration, particularly during dose escalation phases. This article explains the colour-coding system, how to identify your correct dose, and essential safety considerations when using Mounjaro pens.

Understanding Mounjaro Pen Colours and Dosage Identification

Mounjaro (tirzepatide) is a once-weekly injectable medication licensed in the UK for the treatment of type 2 diabetes mellitus and for weight management in adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.^[1][2] The medication is supplied as a multi-dose KwikPen: each pen contains four weekly doses and is used across four consecutive weekly injections, not discarded after a single use. A colour-coded system helps patients and healthcare professionals identify different dosage strengths at a glance. This visual identification system is a safety feature designed to reduce medication errors, but should never be relied upon as the sole identifier.

The colour-coding system serves multiple purposes within clinical practice. It provides a visual reference that helps patients confirm they are using the correct strength, which is particularly important during dose escalation when treatment is being titrated upwards. It also assists healthcare professionals during patient consultations and medication reviews, and helps prevent dispensing errors in pharmacy settings.

Understanding the relationship between pen colour and dosage strength is one element of safe medication administration. It is essential to always verify the strength in milligrams (mg) printed on both the carton and the pen label, rather than relying solely on colour. If there is any uncertainty about pen identification or dosage, patients should contact their GP, diabetes specialist nurse, or community pharmacist before proceeding with an injection.

Mounjaro Colour-Coded Dosing System Explained

Mounjaro KwikPens are available in six dosage strengths in the UK: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each strength has its own colour scheme on the packaging and pen to help with identification. Because colour schemes can vary between markets and may change over time, patients should always primarily rely on the strength in milligrams clearly printed on the carton and pen label.

The graduated dosing system reflects the recommended dose escalation schedule in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA).^[1] Treatment typically commences at 2.5 mg once weekly for four weeks, after which the dose is increased to 5 mg once weekly. Further increases can be made at four-weekly intervals based on individual response and tolerability, up to a maximum of 15 mg once weekly. This stepwise titration approach helps minimise gastrointestinal adverse effects, which are the most commonly reported side effects with tirzepatide therapy.^[1][2] Not all patients will require the maximum dose, and your prescriber will advise on the appropriate pace of escalation for you.

The colour-coding extends to both the pen cap and the label on the pen body, providing visual confirmation of dosage strength alongside the milligram figure printed on the label. Healthcare professionals should educate patients about their specific pen during initiation and at each dose escalation, reinforcing the importance of verifying the strength in milligrams before each injection. Keeping pens in their original packaging until use is a practical way to maintain clear identification, though this is not a labelled storage requirement for the Mounjaro KwikPen.

How to Identify Your Mounjaro Dose by Pen Colour

Correctly identifying your Mounjaro KwikPen before each injection is a fundamental aspect of safe medication practice. Begin by examining the pen whilst it remains in its original packaging. The outer carton will display the dosage strength prominently, and this should match your current prescription. Once removed from the carton, inspect the pen cap colour and cross-reference this with the printed label on the pen body, which states the exact dose in milligrams alongside the colour-coded design.

Patients should establish a routine verification process before each weekly injection. Key identification steps include:

• Check the strength in milligrams (mg) printed on the carton and pen label as the primary identifier

• Note the pen cap colour as a secondary identifier

• Verify the expiry date printed on the pen

• Confirm the solution appears clear and colourless to slightly yellow; do not use if cloudy, discoloured, or if it contains particles^[1]

• If this is not your first injection from the pen, confirm you are within the 30-day in-use period and that the label and pen body are undamaged

• Attach a new pen needle for each injection, as required by the Instructions for Use

It is particularly important to pay careful attention during dose escalation periods when you transition from one strength to another. Your prescriber or diabetes specialist nurse should provide clear instructions about when to change to the next strength, typically after four weeks at each dose level. Some patients find it helpful to mark their calendar or set phone reminders indicating when dose changes are scheduled, alongside noting the new pen strength they should be using.

If you receive a pen that does not match your prescription, or if you are uncertain about which strength you should be using, do not administer the injection. Contact your community pharmacist immediately for clarification, or speak with your GP surgery or diabetes clinic. Never attempt to adjust your dose independently or use a pen strength that differs from your prescription.

Safety Considerations When Using Colour-Coded Mounjaro Pens

Whilst the colour-coded system enhances medication safety, several important considerations remain essential for optimal patient outcomes. Individuals with colour vision deficiency (colour blindness) may experience difficulty distinguishing between certain pen colours. If you have known colour vision impairment, inform your healthcare provider during treatment initiation. Additional safety measures can be implemented, such as clearly labelling pens with the written dose strength, involving a family member or carer in dose verification, or using pharmacy-dispensed labels with large-print dosage information.

Medication storage practices also affect safe pen identification. Mounjaro KwikPens should be stored in a refrigerator (2°C to 8°C) before first use. After first use, the pen can be stored at room temperature not above 30°C for up to 30 days, after which it must be discarded. Do not freeze. There is no requirement in the UK product documents to store the KwikPen in its original carton for light protection; however, keeping it in the carton is a practical way to protect the pen and maintain clear identification. If you store pens of more than one strength simultaneously (for example, during a transition period), keep them in separate, clearly labelled containers to prevent selection errors.

The Mounjaro KwikPen requires a pen needle to be attached by the patient before each injection; a needle is not built into the pen. Before the very first injection from a new pen, the pen must be primed in accordance with the Instructions for Use to remove air from the cartridge and confirm the pen is working correctly. The dose is set using the dose knob and confirmed in the dose window.

Contact your GP or diabetes specialist nurse urgently if:

• You accidentally inject the wrong dose strength

• You experience severe or persistent gastrointestinal symptoms (nausea, vomiting, diarrhoea)

• You develop severe, persistent abdominal pain, possibly radiating to the back (a potential sign of pancreatitis, which has been reported with tirzepatide including serious cases)^[1]

• You notice signs of gallbladder problems (pain in the upper abdomen, fever, yellowing of skin or eyes)

• You experience symptoms of a severe allergic reaction (rash, swelling, breathing difficulties)

• You develop symptoms of hypoglycaemia, particularly if you are also taking insulin or a sulfonylurea, as those medicines may need dose adjustment

• You notice any changes in the appearance of the medication

For severe allergic reactions or if you feel very unwell, contact NHS 111 or call 999 as appropriate. Suspected adverse drug reactions or medication errors can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Always attend scheduled follow-up appointments for monitoring of glycaemic control, weight changes, and treatment tolerability.

Frequently Asked Questions